Pharmacological treatment of insomnia for individuals with brain injury

Journal of Head Trauma Rehabilitation

Volumn 22, Issue 1, 2007, Pages 67-70

  Flanagan, Steven R ^a   Greenwald, Brian ^a   Wieber, Stasia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR; CLONAZEPAM; DIAZEPAM; ESZOPICLONE; HYPNOTIC SEDATIVE AGENT; LORAZEPAM; MELATONIN; MIRTAZAPINE; RAMELTEON; TEMAZEPAM; TRAZODONE; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

AGGRESSION; AMNESIA; ANTEROGRADE AMNESIA; APPETITE; BEHAVIOR THERAPY; BITTER TASTE; BLURRED VISION; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFUSION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTENSION; INSOMNIA; LIVER DYSFUNCTION; LONG TERM CARE; MOTOR DYSFUNCTION; NAUSEA; PRESCRIPTION; PSYCHOMOTOR DISORDER; REBOUND INSOMNIA; REVIEW; SIDE EFFECT; SLEEP; SLEEP DISORDER; SLEEP TIME; SLEEP WALKING; SOMNOLENCE; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

EID: 33846409097     PISSN: 08859701     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001199-200701000-00009     Document Type: Review

References (28)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. American Sleep Disorders Association. The International Classification of Sleep Disorders. Diagnostic and Coding Manual. Rochester, Minn: American Sleep Disorders Association; 1997.
3. Ouellet MC, Beaulieu-Bonneau S, Morin CM. Insomnia in patients with traumatic brain injury: frequency, characteristics and risk factors. J Head Trauma Rehabil. 2006;21:199-212.
4. Wu R, Bao J, Zhang C, Deng J, Long C. Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological therapy for chronic insomnia. Psychother Psychosom. 2006;75:220-228.
5. Grunstein R. Insomnia. Diagnosis and management. Aust Fam Physicians. 2002;31:1-6.
6. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zaolpidem, and zaleplon. Drug Saf. 2003;26:261-282.
7. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162:225-233.
8. Li Pi Shan RS, Ashworth NL. Comparison of lorazepam and zopiclone for insomnia in patients with stroke and brain injury: a randomized, crossover, double-blinded trial. Am J Phys Med Rehabil. 2004;83:421-427.
9. Wagner J, Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev. 2000;4:551-581.
10. Scharf MD, Roth T, Vogel G. A multicenter placebo controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55:192-199.
11. Moen MD, Plosker GL. Zolpidem extended-release. CNS Drugs. 2006;20:419-426.
12. Yanf W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem-sleepwalking: a case report. Arch Phys Med Rehabil. 2005;86:1265-1266.
13. Allen D, Curran HV, Lader M. The effects of single doses of CL 284846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. Eur J Clin Pharmacol. 1993;45:313-320.
14. Walsh JK, Fry J, Erwin CW. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Invest. 1998;16:347-354.
15. Bocca ML, Le Doze F, Etard O, et al. Residuall effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology (Berlin). 1999;143:373-379.
16. Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006;28:491-516.
17. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6:487-495.
18. Obermeyer WH, Benca RM. Effects of drugs on sleep. Neurol Clin. 1996;4:827-840.
19. Rosenberg RP. Sleep maintenance imsomnia. Strengths and weaknesses of current pharmacological therapies. Ann Clin Psychiatry. 2006;18:49-56.
20. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2004;66:469-476.
21. Levenson JL. Prolonged QT interval after trazodone overdose. Am J Psychiatry. 1999;156:969-970.
22. Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Clin Psychiatry. 2003;64:1224-1229.
23. Winokur A, DeMartinis NA III, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry. 2003;64:1224-1229.
24. Wingen M, Bothmer J, Langer S, Ramaekers JG. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry. 2005;66:436-443.
25. Buscemi N, Vandermeer B, Pandya R, et al. Melatonin for the treatment of sleep disorders. Evid Rep Technol Assess. 2004;108:1-151.
26. Roth T, Seiden D, Zee P, et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients. J Am Geriatr Soc. 2005;53:S25.
27. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7:17-24.
28. Bellon A. Searching for new options for treating insomnia: are melatonin and remelteon beneficial? J Psychiatr Pract. 2006;12:229-43.